Milton Park has welcomed Inify Laboratories Limited as the second occupier at its award-winning Nebula development, with the Swedish digital pathology and AI cancer diagnostics company choosing the innovation community for its first UK laboratory.
Inify’s custom-built, AI-enabled facility will help meet the UK’s growing demand for cancer diagnostics, while alleviating pressure on NHS pathology services. The move follows the company’s success in Sweden, where it processes around 80% of Stockholm’s and 10% of the country’s total prostate biopsies.
Read more: MEPC completes £40m sustainable Nebula development at Milton Park
Compared to UK patients who often wait two to three weeks for results, Inify guarantees an answer within five working days in Sweden, with an average turnaround time of just 3.5 days.
Its proprietary AI software, INIFY® Prostate, has been clinically proven to deliver world-leading accuracy with >99% sensitivity and 97% specificity. Every case is then reviewed by a specialist pathologist before a final report is issued.
The Milton Park laboratory brings Inify’s clinical, laboratory, and commercial functions under one roof. Designed for efficiency, the space allows the company to manage every stage of its diagnostic chain — from sample logistics, tissue processing and digitisation through to AI analysis and specialist review.
Kate Bucknall, Managing Director of Inify UK, said:
“Our new base at Milton Park is a real milestone in our mission to improving cancer care and reducing delays in patient pathways. Our recent success shows that digitised, AI-supported workflows can halve the time from biopsy to diagnosis, which has been transformative for both patients and clinicians in Sweden.”
She added:
“With around 120,000 prostate biopsy patients requiring support every year, the UK’s demand for diagnostics is around six times larger than in Sweden. In the UK, our ageing population, growing awareness and a national shortage of pathologists and biomedical scientists mean we have a significant bottleneck in prostate diagnosis.
“We want to tackle that challenge head-on in our new facility, by giving patients answers as soon as possible, while providing quality and efficiency gains across the pathway. The Inify lab will have capacity to handle a volume similar to the country’s total demand.”
Explaining the decision to locate at Milton Park, Kate said:
“After an extensive search, we chose Milton Park based on its vibrant community, strong transport links and access to exceptional talent near Oxford and London. Nebula was also ideal for us to build a state-of-the-art lab from scratch.
“The buildings’ eco-friendly credentials, timber frame and light-filled design aligns with our Scandinavian aesthetic and sustainability approach. The new space is welcoming, for both the Inify team and also for our clinicians and partners. From wellbeing events and sense of community to transport connections, the park is somewhere we feel people will want to come to work.”
Tom Booker, Commercial Manager at MEPC Milton Park, said:
“We’re thrilled that Inify has chosen Milton Park as its UK home. The team’s decision to join the Milton Park community reinforces our position as a home for leading life science and med-tech organisations to collaborate, innovate and grow.
“Inify’s work in Sweden is a real example of how innovation can deliver meaningful impact in healthcare. We look forward to seeing the difference it can make on patient outcomes in its new UK base here at Milton Park.”
Milton Park’s Nebula development offers flexible workspaces for advanced engineering, R&D, and technical operations. Designed to BREEAM ‘Excellent’ standards, Nebula incorporates glulam timber beams that reduced the project’s carbon footprint by 686 tonnes of CO₂ — equivalent to 196 return flights to Hong Kong.
Occupiers also benefit from high power capacity, LED lighting, energy-efficient climate control and EV charging infrastructure.
